Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML

Last updated: February 1, 2017
Sponsor: International Consortium on Acute Leukemias
Overall Status: Active - Recruiting

Phase

N/A

Condition

Leukemia

Acute Myeloid Leukemia

Platelet Disorders

Treatment

N/A

Clinical Study ID

NCT03023384
ICAML2015
  • Ages 18-65
  • All Genders

Study Summary

Create a network of institutions in developing countries that will perform AML diagnosis, risk classification, treatment, supportive care and follow-up evaluation according to a common protocol and will register data using common clinical research forms (CRFs) in a single database and available on the internet.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Acute myeloid leukemia (AML) diagnosis according to WHO criteria;

  2. AML not treated previously, including: de novo AML or secondary to myelodysplasticsyndromes;

  3. Absence of t(15;17), or PML-RARA rearrangement and its variants (acute promyelocyticleukemia diagnosis);

  4. Age greater than or equal to 18 years old or lower than or equal to 65 years old;

  5. Functional status ECOG from 0 to 2;

  6. Signed informed consent;

  7. Ability to follow the protocol procedures;

  8. Willingness to use birth control methods during the treatment until its conclusion;

  9. Adequate renal and liver function:

  • Bilirubin ≤ 1.5x the upper limit of normality;

  • AST and ALT ≤ 2.5x the upper limit of normality;

  • Creatinine ≤ 2.5 mg/dL.

  1. Suitable cardiac function: left ventricular ejection fraction ≥ 50%.

Exclusion

Exclusion Criteria:

  1. Acute promyelocytic leukemia (APL) diagnosis according to WHO criteria;

  2. Diagnosis of acute leukemia of ambiguous lineage, biphenotypic acute leukemia orundifferentiated acute leukemia, according to WHO criteria;

  3. AML previously treated, except with hydroxyurea administration for cytoreduction;

  4. Age greater than 65 years old or lower than 18 years old;

  5. Functional status ECOG greater than 2;

  6. Do not sign the informed consent;

  7. Inability to follow the protocol procedures;

  8. Be fertile female who are unwilling to take any birth control method during thetreatment;

  9. Hypersensitivity to any drug of the treatment protocol;

  10. Positive serology for HIV;

  11. Altered liver and renal function not related to the primary disease (AML):

  • Bilirubin > 1.5x the upper limit of normality

  • AST and ALT > the 2.5x upper limit of normality

  • Creatinine > 2.5 mg/dL n) Altered cardiac function, with LVEF <50%

Study Design

Total Participants: 547
Study Start date:
December 01, 2016
Estimated Completion Date:
January 31, 2022

Study Description

  1. Compare overall survival and disease-free survival of patients with acute myeloid leukemia classified according the European LeukemiaNet treated in participating South American hospitals with the results reported in developed countries.

  2. Compare overall survival and disease-free survival of patients with AML low or intermediate risk treated with two cycles of cytarabine in intermediate dose versus one cytarabine cycle at the same dose followed by autologous SCT as consolidation. The risk will be established according to the classification of the European LeukemiaNet.

  3. Create a network of institutions in developing countries that will perform AML diagnosis, risk classification, treatment, supportive care and follow-up evaluation according to a common protocol and will register data using common clinical research forms (CRFs) in a single database and available on the internet

  4. Using National Reference Laboratories, provide cytogenetic and molecular methods for all institutions participating in the network, thus allowing rapid diagnosis and risk stratification of AML cases according to the European LeukemiaNet structure;

  5. Develop a method of assessing minimal residual disease based on flow cytometry adapted to local resources and capable of guiding therapeutic decisions;

  6. Determine the time interval between: a) diagnosis and risk group determination; b) the first cycle of consolidation chemotherapy and autologous hematopoietic stem cells infusion;

  7. Determine the frequency and etiologic agent of infections associated with treatment, the number and average duration of hospitalization due to episodes of neutropenia;

  8. Create a bank of samples of bone marrow from AML patients at different times of treatment;

  9. Determine the disease-free survival and the cumulative incidence rate of relapse and non-relapse mortality and compare them between chemotherapy alone and chemotherapy plus autologous SCT cohorts.

Connect with a study center

  • Hospital das Clinicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul
    Brazil

    Active - Recruiting

  • Hospital das Clínicas da Unicamp

    Campinas, São Paulo
    Brazil

    Active - Recruiting

  • Hospital das Clinicas de Ribeirão Preto

    Ribeirao Preto, São Paulo
    Brazil

    Active - Recruiting

  • Hospital Mario Covas

    Santo Andre, São Paulo
    Brazil

    Active - Recruiting

  • Hospital de Base de São José do Rio Preto

    Sao Jose do Rio Preto, São Paulo
    Brazil

    Active - Recruiting

  • Hospital São Paulo

    Sao Paulo, São Paulo
    Brazil

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.